Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Braz. j. infect. dis ; 21(1): 1-6, Jan.-Feb. 2017. tab, graf
Artigo em Inglês | LILACS | ID: biblio-839191

RESUMO

Abstract Background: The ideal therapeutic option for ventilator associated pneumonia caused by carbapenem-resistant Enterobacteriaceae is not defined. The aim of this study was to assess mortality-associated risk factors in patients with VAP by CRE and determine the outcome of several treatment options. Methods: This was a retrospective study performed in two tertiary hospitals involving patients with VAP caused by CRE between January 2010 and August 2014. The outcomes were mortality within 30 days of VAP diagnosis and overall mortality during hospital admission. Risk factors for mortality were assessed by comparing variables of survivors and non-survivors. Results: One hundred and twelve patients with CRE-VAP were included, 73 (65%) male, median age 56 years. The 30-day mortality was 57.1% and the overall hospital mortality was 67%. In the binary logistic regression analysis, only age >50 years was independently associated to increased mortality. Polymyxin was the most used drug (47.5%), followed by tigecycline (29.2%) and aminoglycosides (2.4%). Combined therapy with two active drugs was used by 17 patients (20.8%). No therapeutic option was independently associated to survival. However, combined therapy with two active drugs was superior to the therapy with a single active drug when inappropriate therapy was the comparator (p = 0.044). The addition of carbapenem was not associated with increased survival. Conclusion: The best therapeutic option for VAP by CRE is still not completely defined, but the therapy with at least two active drugs was superior in this study.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Carbapenêmicos/uso terapêutico , Farmacorresistência Bacteriana , Infecções por Enterobacteriaceae/mortalidade , Pneumonia Associada à Ventilação Mecânica/mortalidade , Antibacterianos/uso terapêutico , Fatores de Tempo , Modelos Logísticos , Estudos Transversais , Estudos Retrospectivos , Fatores de Risco , Resultado do Tratamento , Mortalidade Hospitalar , Estatísticas não Paramétricas , Enterobacter aerogenes/efeitos dos fármacos , Quimioterapia Combinada/mortalidade , Pneumonia Associada à Ventilação Mecânica/microbiologia , Pneumonia Associada à Ventilação Mecânica/tratamento farmacológico , Klebsiella pneumoniae/efeitos dos fármacos
2.
Rev. bras. cir. cardiovasc ; 31(2): 106-114, Mar.-Apr. 2016. tab, graf
Artigo em Inglês | LILACS | ID: lil-792646

RESUMO

Abstract Introduction: Antiplatelet therapy after coronary artery bypass graft (CABG) has been used. Little is known about the predictors and efficacy of clopidogrel in this scenario. Objective: Identify predictors of clopidogrel following CABG. Methods: We evaluated 5404 patients who underwent CABG between 2000 and 2009 at Duke University Medical Center. We excluded patients undergoing concomitant valve surgery, those who had postoperative bleeding or death before discharge. Postoperative clopidogrel was left to the discretion of the attending physician. Adjusted risk for 1-year mortality was compared between patients receiving and not receiving clopidogrel during hospitalization after undergoing CABG. Results: At hospital discharge, 931 (17.2%) patients were receiving clopidogrel. Comparing patients not receiving clopidogrel at discharge, users had more comorbidities, including hyperlipidemia, hypertension, heart failure, peripheral arterial disease and cerebrovascular disease. Patients who received aspirin during hospitalization were less likely to receive clopidogrel at discharge (P≤0.0001). Clopidogrel was associated with similar 1-year mortality compared with those who did not use clopidogrel (4.4% vs. 4.5%, P=0.72). There was, however, an interaction between the use of cardiopulmonary bypass and clopidogrel, with lower 1-year mortality in patients undergoing off-pump CABG who received clopidogrel, but not those undergoing conventional CABG (2.6% vs 5.6%, P Interaction = 0.032). Conclusion: Clopidogrel was used in nearly one-fifth of patients after CABG. Its use was not associated with lower mortality after 1 year in general, but lower mortality rate in those undergoing off-pump CABG. Randomized clinical trials are needed to determine the benefit of routine use of clopidogrel in CABG.


Assuntos
Humanos , Masculino , Feminino , Complicações Pós-Operatórias/mortalidade , Ticlopidina/análogos & derivados , Inibidores da Agregação Plaquetária/uso terapêutico , Ponte de Artéria Coronária/reabilitação , Revascularização Miocárdica/reabilitação , Alta do Paciente/estatística & dados numéricos , Cuidados Pós-Operatórios/mortalidade , Complicações Pós-Operatórias/tratamento farmacológico , Período Pós-Operatório , Inibidores da Agregação Plaquetária/administração & dosagem , Inibidores da Agregação Plaquetária/normas , Ponte Cardiopulmonar/reabilitação , Aspirina/administração & dosagem , Aspirina/uso terapêutico , North Carolina , Ponte de Artéria Coronária/métodos , Taxa de Sobrevida , Quimioterapia Combinada/mortalidade , Clopidogrel , Revascularização Miocárdica/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA